Market Closed -
Other stock markets
|
After market 05:39:02 pm | |||
141.1 USD | +0.06% | 141.1 | 0.00% |
10:02pm | Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M | MT |
Apr. 29 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.03% | 8.06B | C+ | ||
-1.65% | 104B | B+ | ||
+6.75% | 97.47B | B+ | ||
+5.71% | 22.25B | B | ||
-12.60% | 21.68B | B+ | ||
-9.70% | 18.2B | A- | ||
-39.98% | 17.02B | A- | ||
-10.17% | 16.36B | B | ||
+6.12% | 14.39B | C+ | ||
+35.47% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ASND Stock
- Ratings Ascendis Pharma A/S